

1.0 GENERAL INFORMATION

FEB 21 2003

K024193

1.1 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is _____.

1.1.1. Submitter Name, Address, Contact

Ortho-Clinical Diagnostics, Inc.
100 Indigo Creek Drive
Rochester, New York 14626-5101
(585) 453-4152

Contact Person: Ann M Quinn

1.1.2. Preparation Date

Date 510(k) prepared: December 19, 2002

1.1.3. Device Name

Trade or Proprietary Name:
VITROS Immunodiagnostic Products Troponin I Reagent Pack
VITROS Immunodiagnostic Products Troponin I Calibrators

Common Name : TROPONIN I assay
Classification Name: Troponin I (cTnI) Test System

1.1.4. Predicate Device

The *VITROS* Immunodiagnostic Products Troponin I Reagent Pack and *VITROS* Immunodiagnostic Products Troponin I Calibrators are substantially equivalent to the The *VITROS* Immunodiagnostic Products Troponin I Reagent Pack and *VITROS* Immunodiagnostic Products Troponin I Calibrators (K020662).

1.1.5. Device Description

The *Vitros* Troponin I assay is performed using the *Vitros* Troponin I Reagent Pack and *Vitros* Immunodiagnostic Products Troponin I Calibrators on the *Vitros* ECi Immunodiagnostic System with Intellicheck™. An immunometric technique is used. Cardiac Troponin I present in the sample reacts simultaneously with a biotinylated antibody (mouse monoclonal anti-cTnI) and a horseradish peroxidase (HRP)-labeled antibody conjugate (affinity purified goat polyclonal anti-cTnI). The antigen-antibody complex is captured by streptavidin on the wells. Unbound materials are removed by washing. A reagent containing luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent (a substituted acetanilide) is added to the wells. The HRP in the bound conjugate catalyzes the oxidation of the luminol derivative, producing light. The electron transfer agent increases the level and duration of the light produced. The light signals are read by the *Vitros* ECi System. The amount of HRP conjugate bound is directly proportional to the concentration of cTnI present in the sample.

1.1.6. Device Intended Use

The *VITROS* Troponin I assay is intended for the *in vitro* quantitative measurement of Troponin I (cTnI) in human heparin plasma to aid in the diagnosis of myocardial infarction.

1.1.7. Comparison to Predicate Device

The *VITROS* Immunodiagnostic Products Troponin I Reagent Pack and *VITROS* Immunodiagnostic Products Troponin I Calibrators as modified, are substantially equivalent to the *VITROS* Immunodiagnostic Products Troponin I Reagent Pack and *VITROS* Immunodiagnostic Products Troponin I Calibrators which was cleared by the FDA (K020662) for IVD use.

A modification to the interpretation of results for the assay is being provided to give users further assurance of reporting non biased results.

1.1.8 Conclusions

Introducing a repeat testing algorithm for the *VITROS* Troponin I Assay minimizes the likelihood of an end user obtaining an occasional falsely elevated non repeatable result. This may be of particular concern in cases where a diagnostic decision resulting in medical intervention is based on a single result obtained on a patient above the URL of 0.08 ug/ml.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

FEB 21 2003

Ms. Ann M. Quinn, RAC
Manager, Regulatory Affairs
Ortho Clinical Diagnostics, Inc.
100 Indigo Creek Drive
Rochester, NY 14626-5101

Re: k024193
Trade/Device Name: *VITROS* Immunodiagnostic Products Troponin I Reagent Pack
VITROS Immunodiagnostic Products Troponin I Calibrators
Regulation Number: 21 CFR 862.1215
Regulation Name: Creatine phosphokinase/creatin kinase or isoenzymes test system
Regulatory Class: Class II
Product Code: MMI; JIS
Dated: December 19, 2002
Received: December 20, 2002

Dear Ms. Quinn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 --

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

1.2 Statement of Intended Use

K024193

Page 1 of 1

510(k) Number (if known):

Device Name:


VITROS Immunodiagnostic Products Troponin I Reagent Pack

VITROS Immunodiagnostic Products Troponin I Calibrators

Indications for Use:

For the *in vitro* quantitative measurement of Troponin I (cTnI) in human heparin plasma to aid in the diagnosis of myocardial infarction.

For use in the calibration of the *Vitros* Immunodiagnostic System for the quantitative measurement of cardiac Troponin I (cTnI) in human heparin plasma.



(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K024193

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)